$NTRA News

Morgan Stanley Maintains Overweight on Natera, Raises Price Target to $310

Evercore ISI Group Maintains Outperform on Natera, Raises Price Target to $300

Natera Publishes New Data On Signatera Test In Colon Cancer Study, Test Helps Identify Colon Cancer Patients Who May Benefit From Chemo

Guggenheim Maintains Buy on Natera, Raises Price Target to $290

Natera Partners With Aveta On Late-Stage Head And Neck Cancer Trial

Natera: All-Time Share Price High A Potential Caveat For Investors, Despite Promise

CORRECTION: Bernstein Reinstates Outperform on Natera, Announces $310 Price Target

Natera Secures Landmark Japan Nod For Signatera In Colorectal Cancer

BTIG Maintains Buy on Natera, Raises Price Target to $275

Barclays Maintains Overweight on Natera, Lowers Price Target to $260

BTIG Maintains Buy on Natera, Raises Price Target to $270

Natera Cancer Test Added to NCCN Bladder Cancer Guidelines, Signatera Gets Stronger Support in Bladder Cancer Care

Natera to Showcase Organ Health Leadership with 21 Presentations at the American Transplant Congress

Natera (NTRA), CytoDyn Announce Strategic Collaboration for ctDNA-Guided mCRC Clinical Trials

Goldman Sachs Initiates Coverage on Natera, Inc. (NTRA)

Forget SpaceX Hype: Billionaire Stanley Druckenmiller is Loading Up on This Unknown Healthcare Stock

Natera, Inc. (NTRA) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Natera MRD Leadership Supported by 'Durable' High-Value Market, RBC Says

RBC Capital Reinstates Outperform on Natera, Announces $275 Price Target

Natera Pushes MRD And Panorama Into Treatment Guiding Roles